Seeking New Glues Towards an E3 Ligase-Agnostic Molecular Glue Degrader Identification Platform

Sygnature Discovery has developed a robust, high-throughput, cell-based platform for the discovery and validation of molecular glue degraders. Combining CRISPR-edited HiBiT reporter assays, high-content imaging, and proteome-wide mechanistic deconvolution, this platform support degrader screening, hit confirmation and target engagement analysis.

Study Highlights:

• HiBit and imaging-based assays for high-throughput screening
• Proof-of-concept screens identify known degraders
• Mechanistic deconvolution with LiP-MS

Accelerated Discovery of Molecular Glue Degraders

This platform offers an integrated approach to identifying and characterizing molecular glue degraders. By combining phenotypic screening with unbiased mechanistic follow-up, Sygnature Discovery’s approach supports the development of E3 ligase-targeted strategies in early-stage drug discovery.

Explore our Discovery Chemistry and Platform Screening Expertise

Sygnature Discovery supports targeted protein degradation research through integrated medicinal chemistry and biological screening capabilities. From assay development to proteomics and target engagement, we help identify, validated and characterize novel small molecule degraders.